Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
Short: Van Herk Investments announces 10.07% Shareholding in Ablynx
CategoryEurope news Regions

Short: Van Herk Investments announces 10.07% Shareholding in Ablynx

January 24, 2017 Off By Dino Mustafić

Van Herk Investments B.V. has become owner of more than 10% of Ablynx as it has crossed the 10% threshold and now holds 6,148,362 (10,7%) Ablynx shares.

The investor’s share in the Belgian drugmaker has jumped from 5.40% since August of 2016.

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email a link to a friend (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)

Related

TagsAblynx Van Herk Investments B.V.
Vectura starts with testing asthma drug/device combination for children
Abzena to issue ordinary shares

Popular posts

Medicago, GSK report primary and secondary endpoints with available data met in trial dominated by COVID-19 variants

December 10, 2021 Off

Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)

December 5, 2025 Off
Cosentyx meets the primary endpoints

Cosentyx meets the primary endpoints

June 15, 2015 Off
Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

June 15, 2015 Off
Strensiq in HPP patiens therapy get approval from European Commission

Strensiq in HPP patiens therapy get approval from European Commission

September 13, 2015 Off

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine
Go to mobile version